These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4944698)

  • 1. Electroencephalographic effects of adrenochrome semicarbazone in schizophrenia: quantitative amplitude analysis.
    Sugerman AA; Hyams L
    Res Commun Chem Pathol Pharmacol; 1970 Jan; 1(1):86-98. PubMed ID: 4944698
    [No Abstract]   [Full Text] [Related]  

  • 2. [Semicarbazone adrenochrome sulfonic ester in the treatment of hemorrhagic complications of the terminal chronic uremia patient submitted to extracorporeal hemodialysis with Kill's apparatus].
    Giglio V
    Minerva Urol; 1972; 24(1):16-23. PubMed ID: 4680155
    [No Abstract]   [Full Text] [Related]  

  • 3. Qualitative and quantitative EEG changes of intramuscular thiothixene and trifluoperazine in chronic schizophrenia.
    Akpinar S; Itil TM; Holden JM; Hsu W
    Dis Nerv Syst; 1972 Jan; 33(1):40-5. PubMed ID: 5059688
    [No Abstract]   [Full Text] [Related]  

  • 4. EEG findings in chronic schizophrenics based on digital computer period analysis and analog power spectra.
    Itil TM; Saletu B; Davis S
    Biol Psychiatry; 1972 Aug; 5(1):1-13. PubMed ID: 5042313
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical and electroencephalographic effects of cinanserin in schizophrenic and manic patients.
    Itil TM; Polvan N; Holden JM
    Dis Nerv Syst; 1971 Mar; 32(3):193-200. PubMed ID: 4929084
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationships between measures of the coefficient of variation of the mean absolute EEG voltage and spectral intensities in schizophrenic and control subjects.
    Lifshitz K; Gradijan J
    Biol Psychiatry; 1972 Oct; 5(2):149-63. PubMed ID: 5086956
    [No Abstract]   [Full Text] [Related]  

  • 7. The chronic schizophrenic as a research subject: Toxicity measures and their relationship to efficacy measures.
    Guy W; Cleary P; Bonato RR
    Psychopharmacol Bull; 1970 Oct; 6(4):34-58. PubMed ID: 4936088
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of LSD and ditran in the treatment of therapy resistant schizophrenics (symptom provocation approach).
    Itil TM; Keskiner S; Holden JM
    Dis Nerv Syst; 1969 Feb; 30(2):Suppl:93-103. PubMed ID: 4388281
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical observations on the hemostatic activity of the sulfonic ester of adrenochrome semicarbazone].
    De Biasi R; Berardi G
    Riforma Med; 1965 Jul; 79(30):822-4. PubMed ID: 5319507
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of clinical efficacy of pimozide as maintenance therapy in chronic schizophrenic patients.
    Singh AN
    Curr Ther Res Clin Exp; 1971 Nov; 13(11):695-705. PubMed ID: 5000717
    [No Abstract]   [Full Text] [Related]  

  • 11. Stability studies in schizophrenics and normals using computer-analyzed EEG.
    Itil TM; Saletu B; Davis S; Allen M
    Biol Psychiatry; 1974 Jun; 8(3):321-35. PubMed ID: 4605141
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolongation of P300 latency is associated with the duration of illness in male schizophrenia patients.
    Mori Y; Kurosu S; Hiroyama Y; Niwa S
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):471-8. PubMed ID: 17875024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and reduction of traumatic hematomas with the sulfonic ester of adrenochrome semicarbazone. Clinical observations].
    Quiroli A
    Minerva Chir; 1967 Nov; 22(22):1225-8. PubMed ID: 6074084
    [No Abstract]   [Full Text] [Related]  

  • 14. [Spatial synchronization of alpha-activity in the cerebral cortex in patients with psychoses in advanced age].
    Morozova TV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1967; 67(4):560-7. PubMed ID: 5596944
    [No Abstract]   [Full Text] [Related]  

  • 15. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Possible identification of electroencephalographic changes caused by hereditary and process factors in schizophrenia].
    Kozhushko LF
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1981; 81(3):390-4. PubMed ID: 7196127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dependence of the latent periods of the motor reaction upon the state of alpha activity of the optical cortex in normal people and in the paranoid form of schizophrenia in the process of therapy].
    Puskina WG
    Psychiatr Neurol Med Psychol (Leipz); 1967 Nov; 19(11):421-7. PubMed ID: 6080657
    [No Abstract]   [Full Text] [Related]  

  • 18. N400 abnormalities in late life schizophrenia and related psychoses.
    Olichney JM; Iragui VJ; Kutas M; Nowacki R; Jeste DV
    Biol Psychiatry; 1997 Jul; 42(1):13-23. PubMed ID: 9193737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Spectral power and cortical interactions in the beta2 rhythm in normal subjects and schizophrenic patients].
    Strelets VB; Magomedov RA; Golikova ZV; Novototskiĭ-Vlasov VIu
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2004; 54(2):229-36. PubMed ID: 15174269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral disconnectivity: an early event in schizophrenia.
    Begré S; Koenig T
    Neuroscientist; 2008 Feb; 14(1):19-45. PubMed ID: 17911212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.